REVIVE Webinar: Journal Club: Key findings from recent publications in antimicrobial R&D

Speakers:

• Melis Anahtar, Clinical Investigator, Massachusetts General Hospital (USA)
• Nicole Scangarella-Oman, Scientific Director, GSK (USA)
• Nazgul Sakenova, Postdoctoral Researcher, Harvard Medical School (USA)
• David Paterson, Director, ADVANCE-ID (Singapore)

Moderator: TBC

In this webinar, individuals who have co-authored publications that have had particular impact in the field of antimicrobial R&D will briefly present their findings and answer questions from the audience.

The following articles will be presented:

1. A generative deep learning approach to de novo antibiotic design (Cell, 2025)
2. Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3) (Antimicrobial Agents and Chemotherapy, 2025)
3. Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial (The Lancet Infectious Diseases, 2026)
4. Systematic mapping of antibiotic cross-resistance and collateral sensitivity with chemical genetics (Nature Microbiology, 2025)

Date and time:
Thu, Mar 26, 2026 5:00 PM – 6:30 PM CET

Dedicated registration link here